News - Lucentis, Research

Filter

Current filters:

LucentisResearch

Popular Filters

Positive new data for Novartis drug Lucentis across four indications

Positive new data for Novartis drug Lucentis across four indications

27-09-2013

Novartis has presented new clinical and real world data for its ophthalmic agent Lucentis in more than…

EuropeLucentisNovartisOpthalmicsPharmaceuticalResearch

Cheaper anti-cancer drug as effective as expensive disease-specific agent in treating wet AMD

21-07-2013

An anti-cancer drug has been proven to be equally as effective in treating the most common cause of blindness…

AvastinBiotechnologyEuropeFinancialLucentisNovartisOphthalmicsPharmaceuticalResearchRoche

pSivida and Alimera's Iluvien debuts in Germany; New data on Novartis' Lucentis

08-05-2013

USA-based pSivida Corp (Nasdaq: PSDV), a leader in developing sustained release, drug delivery products…

Alimera SciencesIluvienLucentisMarkets & MarketingNovartisOphthalmicsPharmaceuticalpSividaResearch

Safety of Novartis' Lucentis in VI-DME confirmed with new data; efficacy in CNV

06-09-2012

New data revealed yesterday by Swiss drug major Novartis (NOVN: VX) showed that Lucentis (ranibizumab)…

DiabetesLucentisNovartisOphthalmicsPharmaceuticalRegulationResearchRoche

New study fuels already heated debate - Avastin vs Lucentis

19-06-2012

At the center of the debate of how to potentially save the health care system millions of dollars are…

AvastinLucentisNovartisOphthalmicsPricingResearchRoche

Ophthotech's Fovista tops Lucentis in wet AMD

15-06-2012

Privately-held US biotech firm Ophthotech Corp has announced results from the first clinical trial to…

BiotechnologyFovistaLucentisOphthalmicsOphthotechResearch

Second trial finds Avastin and Lucentis similar for wet-AMD

08-05-2012

One-year results from the UK.'s Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN)…

AvastinLucentisNovartisOphthalmicsPharmaceuticalPricingResearchRoche

Avastin and Lucentis equivalent in treating age-related macular degeneration

02-05-2012

At two years, the cancer drug Avastin (bevacizumab) and the ophthalmic agent Lucentis (ranibizumab injection),…

AvastinLucentisNovartisOphthalmicsPharmaceuticalResearchRoche

Drug approval and launch for Novartis in China, where Quintiles expands

18-01-2012

Swiss drug major Novartis (NOVN: VX) says it has received regulatory approval in China from the State…

Asia-PacificDiabetesGalvusLucentisMarkets & MarketingNovartisOphthalmicsPharmaceuticalQuintilesRegulationResearch

Back to top